Michael Artley Named Senior Director, Information Technology at Acuitas Therapeutics

Michael Artley has joined Acuitas Therapeutics as Senior Director of Information Technology (IT), Abi Coman-Walker, Acuitas’ Chief Operating Officer, announced recently.

Mr. Artley will lead the company’s commitment in ensuring that information, systems, data and innovation continue to support Acuitas Therapeutics in its global mission of advancing human health. Prior to joining the Acuitas team, Mr. Artley was the Chief Information Officer for HSBC Bank Canada. He brings a proven track record of innovation and blue sky thinking to this newly created role.

“Michael joins Acuitas Therapeutics at a critical time in our organization’s growth,” said Ms. Coman-Walker. “Our Board of Directors and the Senior Executive team know that the role of IT is essential in delivering successful, sustainable, efficient outcomes in all aspects of our business model and in ensuring the ability to engage and interact with our global partners. Michael’s experience and expertise – especially in strategic planning around IT – is a key asset in our ability to deliver operational excellence.” She added: “Michael is an inclusive, collaborative leader with an exceptional history in building high-functioning teams. We are thrilled that he has joined Acuitas.”

About Acuitas Therapeutics
Founded in February 2009, Vancouver-based Acuitas Therapeutics (www.acuitastx.com) is a private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles. The company partners with pharmaceutical and biotechnology companies, as well as non-governmental organizations and academic institutes, to advance nucleic acid therapeutics into clinical trials and to the marketplace. The team works with partners to develop new therapies to address unmet clinical needs based on its internationally recognized capabilities in delivery technology. Acuitas Therapeutics has agreements in place with several partners to use its proprietary lipid nanotechnology in the development of COVID-19 vaccines. This includes Pfizer/BioNTech for COMIRNATY, which has received full approval in the U.S. and Canada and is authorized for Emergency Use in Europe, the UK and many other countries. The Acuitas team is currently working on therapeutics focused on addressing cancer, HIV/AIDS, rabies, tuberculosis, malaria and other serious diseases.